Skip to main content
. Author manuscript; available in PMC: 2012 Sep 4.
Published in final edited form as: Oncol Rep. 2011 Jan 14;25(3):855–862. doi: 10.3892/or.2011.1147

Figure 4.

Figure 4

Bevacizumab activates c-Jun. Nude mice were injected with Hec50co endometrial cancer cells and treated with bevacizumab or saline (controls) for 5 weeks. Subsequently, tumors were excised and total cell lysates were isolated. Signaling pathways identified as activated/inhibited by Kinetworks immunoblotting were further tested by immunoblotting lysates from control and bevacizumab-treated tumors. Representative immunoblot shows an increase in phosphorylation levels of c-Jun (upper panel, 45 kDa) in bevacizumab-treated vs. vehicle-treated control group. Actin (lower panel, 40 kDa) was used as a loading control. Densitometric analysis was performed on phospho-c-jun blot, normalized to actin expression, and the relative c-jun phosphorylation (to control, lane 1) is listed below phospho-c-jun blot.